Table 1.

Omalizumab dosing table used in (a) the INNOVATE study (EU dosing table) [13] and (b) the other three Phase III studies (US dosing table) [23–25]; the omalizumab dose was administered by subcutaneous injection every 4 weeks (white cells) or 2 weeks (green-shaded cells)